AMENDMENTS TO THE CLAIMS

Listing of the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-30 (Canceled)

31. (Currently Amended) A compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (l) OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR^{10} or $OCOR^{11}$ wherein R^{10} and R^{11} are as defined above; and R^{1} represents H or a C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_{3} ;

with the proviso that when R¹ is CH₃ and R is OH, then Ar cannot be 3-pyridyl or 4-pyridyl; and

when R¹ is CH₃ and Ar is 3 pyridyl, then R cannot be OCH₂CH=CH₂ or OCH₂C(CH₃)=CH₂.

Claims 32-35 (Canceled)

- 36. (Previously Amended) The compound of claim 31, wherein the substituents on the Ar group are selected from the group consisting of: NHCOCH₃, $N(R^6)(R^8)$, OR^{10} , and $-OCOR^{11}$.
- 37. (Previously Added) The compound of claim 31, wherein Ar is substituted with one or more OR^{10} groups and R^{10} is a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group.
- 38. (Previously Added) The compound of claim 37, wherein R¹⁰ is methyl.
 - 39. (Canceled)
- 40. (Previously Amended) The compound of claim 31, wherein R^{10} is an unsaturated C_{1-6} straight or branched hydrocarbyl group.
- 41. (Previously Added) The compound of claim 40, wherein R is OCH=C(CH₃)₂, OCH₂CMe=CH₂, OCH₂CH=CH₂, or OCH₂C ≡CH.
- 42. (Previously Added) The compound of claim 31, wherein Ar is selected from 3-pyridyl, and 4-pyridyl; and R is selected from OCH=C(CH₃)₂, OCH₂CMe=CH₂, OCH₂CH=CH₂ or OCH₂C ≡CH.
- 43. (Previously Amended) The compound of claim 31, wherein Ar is selected from 3-pyridyl and 4-pyridyl and R is selected from OH, OCH=C(CH₃)₂, OCH₂CH=C(CH₃)₂, OCH₂C(CH₃)=CH₂, OCH₂CH=CH₂, and OCH₂C ≡CH.
- 44. (Previously Added) The compound of claim 31, wherein R^6 and R^8 are the same or different and each is independently H or C_{1-4} alkyl.
- 45. (Previously Added) The compound of claim 31, wherein R^{10} and R^{11} are each independently a saturated or unsaturated C_{1-6} straight chain or branched hydrocarbyl group.

- 46. (Previously Added) The compound of claim 45, wherein R¹⁰ and R¹¹ are selected from methyl, ethyl, n-propyl, and isopropyl.
- 47. (Previously Amended) The compound of claim 31, selected from the group consisting of:
- 1-[4-methyl-7-(2-methylprop-1-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;
 - 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;
 - 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one; and
 - 1 -[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one.

Claims 48 - 54 (Canceled)

55. (Previously Added) A pharmaceutical composition comprising a compound of claim 31 and a pharmaceutically acceptable excipient.

Claims 56 - 57 (Canceled)